Rocket Lab
RKLB
$63.91
-8.69%
Rocket Lab is an end-to-end space company that designs and manufactures launch vehicles (Electron and Neutron) and satellite platforms (Photon), providing frequent and reliable access to space for civil, defense, and commercial customers. As a vertically integrated player, it stands out for its rapid launch cadence and in-house satellite manufacturing, competing with SpaceX and legacy primes in the growing small satellite market. The current investor narrative centers on the transformative acquisition of Iridium, which promises to boost cash flow and scale, but is tempered by integration risks and a high valuation that has led to a sharp pullback from recent highs. Debate remains whether the stock's 32.8% one-year gain reflects sustainable growth or speculative froth.…
RKLB
Rocket Lab
$63.91
Related headlines
Investment Opinion: Should I buy RKLB Today?
Rating: Hold. The thesis is that Rocket Lab offers significant long-term potential driven by revenue growth and the Iridium acquisition, but the current valuation and lack of profitability warrant caution. The analyst consensus is Buy with an average target of $114.33, implying 78.9% upside, but the stock has been in a downtrend.
Supporting evidence includes: (1) Revenue grew 63.5% YoY to $200.3 million in Q1 2026, accelerating from prior quarters. (2) Gross margin expanded to 38.2% from 28.8% a year ago. (3) The forward PS ratio of 14.0x, while still high, is a significant discount to the trailing 61.5x. (4) The company has $1.2 billion in cash and low debt. However, the stock is unprofitable with negative free cash flow, and the trailing PS is 2,360% above the industry average.
Risks that could invalidate the Hold rating: (1) If the Iridium integration fails and revenue growth slows below 20%, the stock could fall to the low target of $77 or below. (2) If the company achieves positive free cash flow within the next two quarters, the thesis would upgrade to Buy. (3) If the stock's PS ratio compresses below 10x forward, it would become more attractive. Overall, the stock appears overvalued relative to its history and peers, but the growth trajectory and analyst targets suggest potential upside if execution improves.
Sign up to view all
RKLB 12-Month Price Forecast
Rocket Lab's growth story is compelling, with revenue accelerating and margins improving. However, the extreme valuation premium and lack of profitability create significant downside risk. The Iridium acquisition is the key swing factor; if successful, it could justify the premium, but if it stumbles, the stock could fall sharply. The neutral stance reflects the balanced risk/reward at current levels. An upgrade to bullish would require evidence of positive free cash flow and successful Iridium integration, while a downgrade to bearish would follow revenue growth deceleration below 30% or a failed acquisition.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rocket Lab's 12-month outlook, with a consensus price target around $114.33 and implied upside of +78.9% versus the current price.
Average Target
$114.33
0 analysts
Implied Upside
+78.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$77 - $150
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of Buy (mean score 1.65 on a 1-5 scale). The average target price is $114.33, implying 78.9% upside from the current price of $63.91. The distribution leans heavily bullish, with 10 recent ratings including 7 Buy/Overweight and 1 Hold. The target range spans from $77.00 (low) to $150.00 (high), with the high target assuming successful integration of Iridium and margin expansion, while the low target reflects risks of execution missteps or competitive pressure. The wide spread indicates high uncertainty, but the strong consensus suggests analysts see significant long-term value despite near-term volatility.
Bulls vs Bears: RKLB Investment Factors
Rocket Lab presents a high-risk, high-reward opportunity. The bull case is supported by accelerating revenue growth (63.5% YoY), expanding gross margins (38.2%), a strong balance sheet, and a consensus analyst target implying 79% upside. However, the bear case highlights extreme valuation (PS ratio 61.5x vs industry 2.5x), continued losses, negative free cash flow, and a steep recent price decline. The single most important tension is whether the Iridium acquisition will successfully transform the company into a cash-flow-generating giant or prove to be a value-destructive integration challenge. Currently, the bear case has stronger evidence given the valuation and profitability concerns, but the bull case could prevail if the acquisition delivers on its promises.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue of $200.3 million grew 63.5% year-over-year, accelerating from 17.5% in Q2 2025. This demonstrates strong demand for launch and space systems services.
- Gross Margin Expansion: Gross margin improved to 38.2% in Q1 2026 from 28.8% a year earlier, indicating improving unit economics as scale increases. This trend supports path to profitability.
- Analyst Consensus Buy with 79% Upside: 15 analysts rate the stock a Buy with an average target of $114.33, implying 78.9% upside from the current price of $63.91. The high target of $150 suggests significant potential.
- Strong Balance Sheet with Low Debt: The company has $1.2 billion in cash and a debt-to-equity ratio of only 0.15, providing financial flexibility to fund growth and the Iridium acquisition.
Bearish
- Extreme Valuation Premium: The trailing PS ratio of 61.5x is 2,360% above the Aerospace & Defense industry average of 2.5x. Even the forward PS of 14.0x implies high growth expectations that may not materialize.
- Continued Net Losses and Negative FCF: Q1 2026 net loss was $45.0 million, and free cash flow was -$77.4 million. Despite revenue growth, the company remains unprofitable with negative cash flows.
- Severe Price Decline and High Beta: The stock has fallen 28.1% over the past 6 months and is down 25.2% in the last month alone. With a beta of 2.553, it is highly sensitive to market downturns.
- Integration Risks from Iridium Deal: The $8 billion Iridium acquisition carries significant integration risks, including potential cost overruns, culture clashes, and execution missteps that could delay expected synergies.
RKLB Technical Analysis
The stock is in a clear downtrend from its 52-week high of $151.00, with the current price of $63.91 representing only 42.3% of the 52-week range (distance from low of $37.57). The 1-year price change of +32.8% masks a severe 28.1% decline over the past 6 months, indicating that the stock has given back most of its earlier gains and is now trading near the lower end of its range, suggesting a potential value opportunity but also risk of further downside if support fails. The 52-week low of $37.57 provides a critical floor, while the high of $151.00 is a distant resistance level.
Beta
2.55
2.55x market volatility
Max Drawdown
-57.5%
Largest decline past year
52-Week Range
$38-$151
Price range past year
Annual Return
+32.8%
Cumulative gain past year
| Period | RKLB Return | S&P 500 |
|---|---|---|
| 1m | -25.2% | +1.4% |
| 3m | -19.8% | +3.3% |
| 6m | -28.1% | +6.3% |
| 1y | +32.8% | +16.0% |
| ytd | -15.9% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RKLB Fundamental Analysis
Revenue has grown strongly, with Q1 2026 revenue of $200.3 million up 63.5% year-over-year, accelerating from the 17.5% growth in Q2 2025. The revenue mix is split between product ($127.5M) and service ($72.9M), with the Iridium acquisition expected to further boost service revenue. However, the company remains unprofitable, with a net loss of $45.0 million in Q1 2026, though the net loss margin improved to -22.5% from -49.5% a year earlier. Gross margin has expanded to 38.2% from 28.8% in Q1 2025, indicating improving unit economics as scale increases. The company has a strong balance sheet with $1.2 billion in cash and a debt-to-equity ratio of only 0.15, but free cash flow remains negative at -$77.4 million in Q1 2026, though the Iridium acquisition is expected to improve cash flow. ROE is -11.5%, reflecting ongoing losses, but the current ratio of 4.08 provides ample liquidity.
Quarterly Revenue
$200348000.0B
2026-03
Revenue YoY Growth
+63.5%
YoY Comparison
Gross Margin
38.2%
Latest Quarter
Free Cash Flow
$-316301000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RKLB Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 61.5x, while the forward PS ratio (based on estimated revenue of $2.64B) is approximately 14.0x, implying the market expects significant revenue growth. Compared to the Aerospace & Defense industry average PS ratio of 2.5x, Rocket Lab trades at a massive 2,360% premium, reflecting its high-growth status and unique space exposure. Historically, the stock's PS ratio has ranged from 21x to 194x over the past two years; the current 61.5x is above the midpoint, suggesting the market still prices in optimistic growth expectations despite the recent pullback.
PE
-188.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-234.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Rocket Lab remains unprofitable with a net loss of $45.0 million in Q1 2026 and negative free cash flow of -$77.4 million. The net loss margin improved to -22.5% from -49.5% a year ago, but the company still burns cash. With a debt-to-equity ratio of 0.15 and $1.2 billion in cash, the balance sheet is strong, but the negative ROE of -11.5% indicates ongoing shareholder value destruction. The Iridium acquisition adds integration risk and could strain cash flows if synergies are delayed. Revenue concentration is also a risk, as the top customer or program could represent a significant portion of sales.
Market & Competitive Risks: The stock trades at a massive premium with a trailing PS ratio of 61.5x, far above the industry average of 2.5x, making it vulnerable to valuation compression if growth slows. With a beta of 2.553, the stock is highly correlated to market movements and would suffer disproportionately in a downturn. Competitive threats from SpaceX's reusable rockets and Boeing's large satellite contracts could erode market share. Recent news of a Boeing $2 billion satellite contract highlights the competitive landscape. Additionally, the stock has declined 28.1% over the past 6 months, indicating negative momentum.
Worst-Case Scenario: If the Iridium acquisition fails to deliver expected synergies, revenue growth decelerates, and the company continues to burn cash, the stock could fall to its 52-week low of $37.57, representing a 41.2% decline from the current price of $63.91. In a severe market downturn, the stock could even break below that level, given its high beta. The maximum drawdown historically is -57.46%, which would imply a price of approximately $27.20. Investors could lose 35-57% of their investment in an adverse scenario.
FAQ
The key risks include: (1) Financial risk: The company is unprofitable with a net loss of $45.0 million in Q1 2026 and negative free cash flow of -$77.4 million, though the balance sheet is strong with $1.2 billion cash. (2) Valuation risk: The trailing PS ratio of 61.5x is extremely high, making the stock vulnerable to sharp declines if growth slows. (3) Integration risk: The $8 billion Iridium acquisition could face execution challenges, delaying expected synergies. (4) Competitive risk: SpaceX dominates launch with reusable rockets, and Boeing recently won a large satellite contract, intensifying competition. The most severe risk is a failed integration leading to a 41% decline to the 52-week low of $37.57.
The 12-month forecast is mixed, with three scenarios: Bull case (25% probability) sees the stock reaching $114-$150, driven by successful Iridium integration and Neutron launch. Base case (50% probability) targets $77-$114, assuming moderate growth and stable margins. Bear case (25% probability) sees the stock falling to $37-$77 if integration fails or growth decelerates. The base case is most likely, with the stock trading near the analyst average target of $114.33, implying 78.9% upside from the current price of $63.91. However, the wide range reflects high uncertainty. Key assumptions include revenue growth of 40-50% and gross margins above 38%.
Rocket Lab appears significantly overvalued based on traditional metrics. The trailing price-to-sales (PS) ratio is 61.5x, compared to the Aerospace & Defense industry average of 2.5x, a premium of 2,360%. Even the forward PS ratio of 14.0x, based on estimated revenue of $2.64 billion, is well above the industry median. Historically, the stock's PS ratio has ranged from 21x to 194x over the past two years; the current 61.5x is above the midpoint, suggesting the market still prices in optimistic growth expectations. The high valuation implies that investors expect continued rapid revenue growth and eventual profitability. If growth disappoints, the stock could see significant multiple compression.
Rocket Lab is a high-risk, high-reward stock that may be suitable for aggressive growth investors. The analyst consensus is Buy with an average target of $114.33, implying 78.9% upside from the current price of $63.91. However, the stock trades at a trailing PS ratio of 61.5x, far above the industry average of 2.5x, and the company is not yet profitable. The biggest downside risk is integration failure with the Iridium acquisition, which could send the stock to the 52-week low of $37.57. For investors with a long-term horizon and high risk tolerance, it could be a good buy at current levels if they believe in the growth story. For conservative investors, it is likely too speculative.
Rocket Lab is better suited for long-term investment due to its high volatility and speculative nature. With a beta of 2.553, the stock is highly sensitive to market movements, making short-term trading risky. The company is in a growth phase with negative earnings, so it may take several years to achieve profitability. The Iridium acquisition is a multi-year catalyst. A minimum holding period of 3-5 years is recommended to allow the growth story to play out. Short-term traders may find opportunities in the stock's wide price swings, but the 28.1% decline over the past 6 months highlights the downside risk. The stock pays no dividend, so returns depend entirely on price appreciation.